89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma
NCT01859234 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2013-05-21
Summary
The purpose of this study is to see whether 89Zr-bevacizumab PET scanning is feasible in relapsing multiple myeloma patients.
Conditions
Interventions
- DRUG
-
89Zr-bevacizumab
89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
Sponsors & Collaborators
-
University Medical Center Groningen
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-05-31
- Primary Completion
- 2014-05-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Relevance of [68Ga]Ga -PentixaFor-PET for Initial Staging and Therapeutic Evaluation of Multiple Myeloma
NCT04561492 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Non-invasive Imaging of Cetuximab-Zr. 89 Uptake Wit PET: a Phase I Trial in Stage IV Cancer Patients
NCT00691548 ·Status: COMPLETED ·Phase: PHASE1
-
A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
NCT05448404 ·Status: UNKNOWN ·Phase: NA
-
Pembrolizumab-PET Imaging
NCT02760225 ·Status: COMPLETED ·Phase: NA
-
PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy?
NCT00628940 ·Status: COMPLETED ·Phase: PHASE1
-
89Zr-labeled NY009 PET Imaging in Patients
NCT05691855 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
MRI and PET to Assess Pembrolizumab Response
NCT02591654 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
CD8 PET Imaging in Metastatic Solid Tumours
NCT06534190 ·Status: RECRUITING ·Phase: PHASE2
-
MPDL3280A-treatment-IST-UMCG
NCT02478099 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
NCT04258592 ·Status: TERMINATED ·Phase: PHASE1
-
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
NCT03573986 ·Status: TERMINATED ·Phase: PHASE1
-
89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors
NCT01338090 ·Status: COMPLETED
-
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role
NCT04333524 ·Status: ACTIVE_NOT_RECRUITING
-
ImmunoPET With an Anti-CD8 Imaging Agent
NCT04029181 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Noninvasive Detection and Assessment of Therapy Response in Multiple Myeloma Using Whole-Body MRI
NCT04493411 ·Status: TERMINATED ·Phase: NA
-
89Zr-labeled NY008 PET Imaging in Patients
NCT05655676 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma
NCT04566185 ·Status: COMPLETED ·Phase: NA
-
Study of Hypoxia Measured in F-Miso PET/Scan and MRI in Patients With Squamous Cells Carcinoma
NCT04031534 ·Status: COMPLETED ·Phase: PHASE2
-
⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors
NCT03802123 ·Status: COMPLETED ·Phase: PHASE2
-
FET-PET for Evaluation of Response of Recurrent GBM to Avastin
NCT01756352 ·Status: COMPLETED ·Phase: PHASE2
-
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
NCT05892393 ·Status: RECRUITING ·Phase: PHASE1
-
Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET)
NCT01081613 ·Status: COMPLETED
-
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
NCT04955262 ·Status: WITHDRAWN ·Phase: PHASE1
-
Comparison Between FDG-PET and MRI for the Assessment of Response to Intensive Chemotherapy in Multiple Myeloma Patients.
NCT00200668 ·Status: TERMINATED ·Phase: NA
-
PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
NCT06871176 ·Status: RECRUITING ·Phase: NA